M&A Deal Summary

Treadwell Therapeutics Acquires TCRyption

On October 15, 2021, Treadwell Therapeutics acquired life science company TCRyption

Acquisition Highlights
  • This is Treadwell Therapeutics’ 1st transaction in the Life Science sector.
  • This is Treadwell Therapeutics’ 1st transaction in Canada.
  • This is Treadwell Therapeutics’ 1st transaction in Ontario.

M&A Deal Summary
Date 2021-10-15
Target TCRyption
Sector Life Science
Buyer(s) Treadwell Therapeutics
Deal Type Add-on Acquisition

Target

TCRyption

Toronto, Ontario, Canada
TCRyption is a preclinical company focused on the development of novel approaches to TCR based cellular therapy for cancer and other indications. TCRyption is based in Toronto, Ontario.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Treadwell Therapeutics

New York, New York, United States
Category Company
Sector Life Science
DESCRIPTION

Treadwell Therapeutics is a clinical-stage oncology company developing first-in-class and best-in-class small molecules to address unmet needs in patients with cancer. Treadwell Therapeutics is based in New York.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Ontario) 1 of 1
Country (Canada) 1 of 1
Year (2021) 1 of 1
Mergr

Product

Company

Legal